Additional file 1 of Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial

Additional file 1: Table S1. Baseline demographics and clinical characteristics in ASPECT-NP participants with ventilated hospital-acquired vs those with ventilator-associated bacterial pneumonia (ITT population, both treatment arms combined). Table S2. Baseline microbiologic assessment in ASPECT-NP participants with ventilated hospital-acquired bacterial pneumonia (ITT population). Table S3. Susceptibility of baseline Pseudomonas aeruginosa and Enterobacterales to key antibacterial agents, by treatment arm, in ASPECT-NP participants with ventilated hospital-acquired bacterial pneumonia (ITT population). Table S4. Baseline microbiologic assessment in ASPECT-NP participants with ventilated hospital-acquired vs those with ventilator-associated bacterial pneumonia (ITT population, both treatment arms combined). Table S5. Baseline bacterial pathogen isolates from blood cultures in the ventilated HABP subgroup, by treatment arm (ITT population). Table S6. 28-day all-cause mortality in participants with vHABP, by clinical characteristics evaluated in the multivariable analysis (ITT population). Table S7. Odds ratio estimates (and confidence intervals) for risk of death due to any cause by day 28 associated with the significant factors in the sensitivity logistic regression model. Figure S1. Methodology and general results of the multivariable analysis. Figure S2. Frequency distribution of meropenem MIC values for (A) Enterobacterales (N = 80 isolates) and (B) Pseudomonas aeruginosa (N = 19) isolates obtained from participants with vHABP of the meropenem arm.